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Abstract
Background: Based on the AHA/NHLBI-definition three out of five cardiometabolic traits must be present for the
diagnosis of the metabolic syndrome (MetS), resulting in 16 different combination types. The associated cardiovascular
risk may however be different and specific combination may be indicative of an increased risk, furthermore little is
known to which extent these 16 combinations contribute to the overall prevalence of MetS. Here we assessed the
prevalence of all 16 combination types of MetS, analyzed the impact of age and gender on prevalence rates, and
estimated the 10-year risk of fatal and non-fatal myocardial infarction (MI) of each MetS combination type.
Methods: We used data of the German Metabolic and Cardiovascular Risk Project (GEMCAS), a cross-sectional
study, performed during October 2005, including 35,869 participants (aged 18-99 years, 61% women). Age-
standardized prevalence and 10-year PROCAM and ESC risk scores for MI were calculated.
Results: In both men and women the combination with elevated waist-circumference, blood pressure and glucose
(WC-BP-GL) was the most frequent combination (28%), however a distinct unequal distribution was observed
regarding age and sex. Any combination with GL was common in the elderly, whereas any combination with
dyslipidemia and without GL was frequent in the younger. Men without MetS had an estimated mean 10-year risk
of 4.7% (95%-CI: 4.5%-4.8%) for MI (PROCAM), whereas the mean 10-year risk of men with MetS was clearly higher
(age-standardized 7.9%; 7.8-8.0%). In women without MetS the mean 10-year risk for MI was 1.1%, in those with
MetS 2.3%. The highest impact on an estimated 10-year risk for MI (PROCAM) was observed with TG-HDL-GL-BP in
both sexes (men 14.7%, women 3.9%). However, we could identify combinations with equal risks of non-fatal and
fatal MI compared to participants without MetS.
Conclusions: We observed large variations in the prevalence of all 16 combination types and their association to
cardiovascular risk. The importance of different combinations of MetS changes with age and between genders
putting emphasis on a tailored approach towards very young or very old subjects. This knowledge may guide
clinicians to effectively screen individuals and prioritize diagnostic procedures depending on age and gender.
Background
The metabolic syndrome (MetS) is defined as a cluster of
risk factors which predispose an individual to diabetes
mellitus type 2 and cardiovascular disease [1,2]. According
to the most widely used definition for the diagnosis of
MetS - the National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III [3] and their modifica-
tion from the AHA/NHLBI [4] - at least three out of five
cardiovascular or cardiometabolic traits must be present
to diagnose MetS: (1) elevated blood glucose or known
diabetes mellitus (GL), (2) increased waist circumference
(WC), (3) increased triglycerides (TG), (4) low high density
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any medium, provided the original work is properly cited.lipoprotein cholesterol (HDL) and (5) elevated blood pres-
sure (BP). This definition allows 16 possible combinations
for a diagnosis of MetS.
There is a controversial debate about the usefulness of
the concept of the MetS [5-10]. One of the criticisms
refers to underlying implicit assumption that each com-
bination type of the MetS uniformly increases risk for
cardiovascular outcomes. Numerous studies addressed
partly this issue by investigating the effect of the num-
ber of MetS-defining traits. These studies show a gra-
dual increase in risk of cardiovascular outcomes with
numerically increasing traits [11,12]. Accordingly, pre-
vious studies reported a progressive increase for cardio-
vascular outcomes in those individuals diagnosed with
MetS consisting of 5 traits compared to those diagnosed
with MetS consisting of only 3 traits [13-17].
However, epidemiologic data on the distribution of the
16 combination types are sparse and little is known to
which extent these 16 combinations contribute to the
overall prevalence of MetS. Previous studies have
focused on the prevalence of the number of MetS com-
ponents. To the best of our knowledge there has been
only one study that compared the prevalence of all
MetS combinations. This study included 4 different stu-
dies from the Asia-Pacific region [18]. Furthermore, pre-
valence data according to age, sex and cardiovascular
disease are missing and not much is known, whether
different combinations translate into a differential risk
for the incidence of cardiovascular events [19]. Usually
such detailed analyses are hampered by small sample
sizes. The knowledge of these associations might man-
date physicians to effectively screen subjects and priori-
tize diagnostic steps depending on age and gender.
The German Metabolic and Cardiovascular Risk Pro-
ject (GEMCAS) is a point prevalence study including
35,869 participants with an age-range of 18-99 years,
aiming to determine the prevalence of the MetS in Ger-
many [20,21]. The present analysis was undertaken (1)
to determine the prevalence of the 16 possible combina-
tion types of MetS according the AHA/NHLBI defini-
tion, (2) to analyze the impact of age and gender on
prevalence, and (3) to associate the different combina-
tion types to the 10-year risk of fatal and non-fatal car-
diovascular disease based on PROCAM and ESC score
estimates.
Methods
Design and subjects
GEMCAS was conducted during two weeks in October
2005 at 1,511 randomly selected primary care physicians
across Germany. Physicians specialized in cardiology
and/or diabetes treatments were excluded because of
the assumed higher prevalence of the MetS in their cli-
entele. Methods have been previously described in detail
[20,21]. In short, all eligible subjects aged ≥18 years vis-
iting a general practitioner regardless of the reason of
their visit were included. The study was planned and
conducted according to the German guidelines for
Good Epidemiology Practices (GEP) [22]. All partici-
pants gave their written informed consent and the study
protocol was approved by the institutional ethics
committee.
Data collection
Data were collected on sociodemographic variables,
smoking habits, and lifestyle aspects. The participating
physicians recorded a history of diabetes mellitus (DM)
and cardiovascular disease (CVD), the latter defined as
myocardial infarction and stroke. Further a standardized
assessment according to the study protocol for all risk
factors required for diagnosis of MetS - WC, BP, GL,
TG and HDL - was carried out. For blood sampling a
two-step approach was performed [21]. First, all subjects
were included regardless of fasting status. By using a
blood glucose quick test, it was possible to directly
exclude or diagnose hyperglycaemia, independent of the
subject’s fasting state, based on the selected capillary
blood glucose concentration cut points of <5.56
or >11.11 mmol/L. If the findings concerning blood glu-
cose or triglycerides were ambiguous due to a meal in
the previous 8 respective 12 hours, the subject was
asked to come for a second appointment to give a fast-
ing blood sample. All blood samples were shipped
within 24 hours to a central laboratory (Berlin,
Germany) by an assigned courier service. Participating
physicians were equipped from the central laboratory
with tubes containing the glycolysis inhibitor sodium
fluoride, which ensured that the samples could be stored
at room temperature for up to 24 hours [23].
Quality assurance
To reduce the logistics of coordinating such a large,
country-wide study, participating GPs received no other
instructions than the information material sent to them
by mail prior to the survey. To control for a proper pro-
cedure and to ensure the robustness of the data
obtained, a specifically adapted monitoring system was
designed to meet the high logistic needs [21]. This mon-
itoring concept included telephone-monitoring and ran-
dom on-site visits. Telephone monitoring was
performed at >50% of the enrolled sites prior to the day
of the survey to ensure all participating physicians had
the complete and correct set of forms, documents and
blood sampling materials available on the survey day.
Physicians to be included in telephone monitoring were
selected randomly but stratified by the 3 recruitment
groups. After the phone call the interviewers rated the
monitored site based on the interview results. On-site
Moebus et al. Cardiovascular Diabetology 2010, 9:34
http://www.cardiab.com/content/9/1/34
Page 2 of 12visits were performed on the day of the survey, with a
focus on quality of data and measurements. Monitoring
visits were planned in at least 10% of the participating
medical practices. A priori, these practices were chosen
at random though proportional to the 3 recruitment
groups. Some sites that received a poor rating after the
telephone monitoring were to be specifically included in
the on-site monitoring, if possible.
Definition of the MetS
We defined MetS according to AHA/NHBLI 2004 [4].
This includes the presence of any three of the following
five traits: (a) WC > 102 cm in men or >88 cm in
women, (b) TG ≥ 1.7 mmol/L (150 mg/dl), (c) HDL <
1.08 mmol/L (40 mg/dl) in men and <1.3 mmol/L (50
mg/dl) in women, (d) BP ≥ 130/≥85 mmHg and (e) fast-
ing GL ≥ 5.6 mmol/L (100 mg/dl) or random GL ≥ 11.1
mmol/L (200 mg/dl) or known diabetes. In accordance
with the definition of 2004, we have performed the fol-
lowing adjustments: We used here the recommended
lowered cutpoint of GL ≥ 5.6 mmol/L (100 mg/dl)
according to a footnote in table 1 of the original publi-
cation[4]). Furthermore we included a history of dia-
betes and a random GL > 11.1 mmol/L since in the
NHLBI/AHA Conference Proceedings 2004 it was
claimed, that the primary clinical outcome MetS was
identified as CVD [4].
Statistical analyses
For all analyses SAS (Version 9.2) was used. Subjects’
characteristics were calculated as means for continuous
variables and frequency for all categorical variables.
Age-standardized prevalence rates were also calculated
to compare the prevalence of cardiovascular comorbid-
ities with the different combinations. We used direct
age-standardization and their 95%-confidence intervals
(CI) [24] according to the German population 2004 [25].
To avoid minimal cell counts we categorized age in fol-
lowing groups: 18-40, 41-60, 61-80, and 81-99.
Finally we analyzed the association of all 16 combina-
tions with the 10-year risk of fatal and nonfatal myocar-
dial infarction (MI) using the PROCAM score for men
(aged 35-65 years) and modified for women (aged 45-65
years) [26]. The ESC Score for men (aged 35-65 years)
and for women (aged 45-65 years) was calculated as
well [27]. We calculated age-standardized risk estimates
stratified by sex, using the direct standardization with
age groups (according to PROCAM and ESC) 35-42, 43-
49, 50-57 and 58-65 in men; and 45-51, 52-58 and 59-
65 in women, respectively. We used participants without
MetS as the standard population.
For all combination analysis, we performed complete
case analyses and made sure that subjects falling under
one combination of the higher order (e.g. 4 risk factors
present) are not simultaneously falling under the combi-
nations with lower order and less criteria (e.g. any 3 of
the above mentioned 4).
Results
Baseline characteristics
GEMCAS included 13,942 men (38.9%) and 21,927
women with a mean age of 53 and 50.9 years respec-
tively (Table 1). In 2,768 participants MetS was not
definable because of missing traits. About 70% of men
and 54% of women either were overweight (25-30 kg/
m
2) or obese (≥30 kg/m
2). Current smokers were 27.5%
of men and 23.5% of women and 20.5% of men and
10.5% of women had a history of cardiovascular disease.
The mean age of subjects with MetS was higher for
both genders as was the degree of obesity (Table 1).
Levels of TG, GL and BP and average intake of medica-
tion (drugs against hypertension and dyslipidemia) were
generally higher in subjects with MetS compared to
those without MetS.
Frequency of risk factor combinations
Three traits had 66% of men and 64% of women, 27/
28% had four traits and 6%/8% had 5 traits. Figure 1 dis-
plays the distribution of the different combinations that
make up the MetS and their relative frequency. WC-BP-
GL was the most frequent combination in both men
and women (both 28%). The combination of WC-HDL-
BP was much more frequent in women than in men (10
vs. 3%), whereas TG-BP-GL was much more frequent in
men than women (10 vs. 3%). In women, the 8 combi-
nations with the highest prevalence involved an elevated
blood pressure (in men 7 out of 8 combinations). In
b o t hs e x e s ,5o u to f8i n v o l v e da ni n c r e a s e dw a i s t
circumference.
I nT a b l e2t h ep r e v a l e n c eo fc o m b i n a t i o n si sp r e -
sented by sex and age-groups. The combination of WC-
TG-BP was most frequent in younger men (18-30 years:
38%; 31-46: 22%; 46-60: 17%; 61-75: 10%; >76 years:
8%), almost the same combination was most frequent in
older men, except that TG was exchanged by GL (WC-
B P - G L :2 ,1 5 ,2 6 ,3 4 ,3 6 %r e s p . ) .I n t e r e s t i n g l y ,n o n eo f
the combinations types most frequent in the younger
men had an elevated blood glucose included, all combi-
nations types including elevated blood glucose were
more prevalent in the elderly - with the exception of
those combinations types not including elevated blood
pressure. The prevalence of these combinations was
either not different between younger and older men or
tended to be higher in younger men.
In women, a similar observation applied except that
WC-HDL-BP was the most frequent combination in
younger women, with a large difference between
younger and older women (40, 28, 10, 4, 4%, resp.).
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WC-BP-GL (both genders) with slightly lesser inclines
for TG-BP-GL and WC-TG-GL (men > women); these
combinations included no subjects with low HDL.
Combination types and 10-year risk for myocardial
infarction (PROCAM)
According to the PROCAM algorithm the analysis of
the 10-year risk for MI for different combination types
was computed for the age groups of 35-65 years in
men (Figure 2) and 45-65 years in women (Figure 3).
Overall, the estimated risk was substantially higher in
men than in women throughout every possible
combination.
Men without MetS had a mean 10-year risk of 4.7%
(95%-CI: 4.5%-4.8%), whereas the mean 10-year risk of
men with MetS was clearly higher (age-standardized
7.9%; 7.8%-8.0%). As expected all 16 combinations per-
formed higher risk scores compared to men without
MetS (Figure 2). However, we observed large differences
between the combinations. Compared to the mean 10-
year risk of all men with MetS, three combinations per-
formed significant lower 10-years risk estimates, all
including elevated waist-circumference and blood
Table 1 Characteristics of the total study population and individuals with and without the Metabolic Syndrome
Risk factor/Trait All
(n = 35,869)
Without MetS*
(n = 25,961)
With MetS*
(n = 7,122)
Men Women Men Women Men Women
N (%) 13,942 (38.9) 21,927 (61.1) 9,452 (36.4) 16,509 (63.6) 3,168 (44.5) 3,954 (55.5)
Age (years), mean ± SD 53.0 ± 15.8 50.9 ± 16.2 50.9 ± 16.3 48.1 ± 15.9 58.8 ± 12.9 60.5 ± 13.9
Weight (kg), mean (±SD) 86.2 ± 14.9 71.9 ± 15.2 81.7 ± 12.2 68.3 ± 13.1 97.1 ± 15.3 84.5 ± 15.9
Body Mass Index (%)
≤25 kg/m
2 29.7 46.4 40.4 57.9 4.3 8.0
25 - <30 kg/m
2 45.6 30.3 47.7 28.9 38.6 33.1
≥30 kg/m
2 24.7 23.3 11.9 13.1 57.1 58.9
Waist circumference (cm), mean ± SD 98.8 ± 13.0 86.8 ± 14.3 94.1 ± 10.9 82.5 ± 12.0 110.4 ± 10.7 101.6 ± 11.8
Blood parameters
Blood glucose (mmol/l), mean ± SD 5.7 ± 2.0 5.3 ± 1.6 5.2 ± 1.4 4.9 ± 0.9 7.1 ± 2.9 6.7 ± 2.6
Total Cholesterol (mmol/l), mean ± SD 5.3 ± 1.1 5.4 ± 1.1 5.2 ± 1.0 5.3 ± 1.0 5.3 ± 1.2 5.6 ± 1.1
HDL (mmol/l), mean ± SD 1.4 ± 0.4 1.7 ± 0.4 1.5 ± 0.4 1.8 ± 0.4 1.2 ± 0.3 1.4 ± 0.4
LDL (mmol/l), mean ± SD 3.3 ± 0.9 3.3 ± 0.9 3.3 ± 0.9 3.2 ± 0.9 3.3 ± 1.0 3.5 ± 1.0
Triglycerides (mmol/l), median(Q1; Q3) 1.6 (1.1;2.4) 1.3 (0.9;1.9) 1.4 (1.0;1.9) 1.2 (0.9;1.5) 2.4 (1.7;3.4) 2.1 (1.6;2.9)
Blood Pressure (BP)
Systolic BP (mmHg), mean ± SD 133.6 ± 18.2 128.5 ± 19.3 129.9 ± 17.4 124.4 ± 17.9 142.7 ± 16.8 142.7 ± 17.5
Diastolic BP (mmHg), mean ± SD 81.4 ± 10.4 79.2 ± 10.6 79.9 ± 10.0 77.6 ± 10.2 84.9 ± 10.5 84.5 ± 10.4
Smoking status (%)
Current Smoker 27.5 23.5 28.7 24.6 23.7 18.9
Past Smoker 39.8 22.3 35.4 22.4 50.3 21.6
Never Smoker 32.8 54.2 35.9 53.0 26.0 59.5
MetS Traits (%)
WC 36.4 41.5 17.1 26.3 84.1 92.8
TG 24.0 12.9 12.1 4.6 63.7 53.4
HDL 12.2 13.9 4.6 5.6 32.8 46.8
BP 66.6 52.9 55.8 41.8 92.5 91.6
GL 29.5 17.6 13.1 5.3 75.6 68.1
Pharmacotherapy (%)
Anti-diabetic 12.0 7.0 4.9 1.6 34.2 30.1
Anti-hypertensive 41.7 34.2 32.3 25.0 67.3 67.8
Lipid lowering 18.1 10.5 14.0 6.9 29.5 24.6
Comorbidities (%)
Cardiovascular diseases 20.5 10.5 16.5 7.2 31.7 22.9
Cancer 5.5 4.9 5.2 4.3 6.7 7.1
*Of n = 2,768 subjects MetS was not definable because of missing traits
MetS, Metabolic Syndrome (for cut points used see methods); BMI, Body Mass Index; SD, Standard Deviation; HDL, High Density Lipoprotein; LDL, Low Density
Lipoprotein; BP, Blood Pressure; WC, waist circumference; TG, triglyceride; BP, blood pressure; GL, blood glucose
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sure (WC-BP-GL, WC-TG-GL, and WC-HDL-GL).
Furthermore, all three combinations were more frequent
in the older men (cf. table 2). The highest 10-year risk
for MI in men was found with the combinations TG-
HDL-BP-GL (14.7%; 13.6%-15.9%) and TG-HDL-GL
(14.5%; 12.2%-17.2%), both not including elevated waist
circumference. Interestingly, all combinations that were
frequent in the younger men (cf. table 2) resulted in
medium to high risk scores (8.6%-11%). Out of the 5
combinations with the highest risk (>10%), 4 included
GL, 4 BP and 2 WC.
Women without MetS had a mean 10-year risk of 1.1%
(1.1-1.2%), whereas the mean 10-year risk of the women
with MetS was twice as high (age-standardized 2.3%).
Interestingly, we found two combinations with similar 10-
year risks compared to women without MetS (WC-HDL-
GL: 1.0%; 0.5%-1.7% and WC-BP-GL: 1.7%; 0.7%-3.3%). As
in men, we observed a large variation between the combi-
nations. Compared to the mean 10-year risk of all women
with MetS, we observed three combinations with lower
10-years risk estimates (Figure 3), all including elevated
waist circumference (WC-HDL-GL, WC-BP-GL, WC-
TG-BP), but - different to men - we found one combina-
tion with elevated blood pressure. Comparable 10-years
risk estimates were observed mainly in older women
(WC-TG-GL, TG-BP-GL, WC-HDL-BP-GL and
WC-TG-HDL-GL). Noticeably, two of these combinations
included four risk factors. The highest estimated risks
were observed with the combination TG-HDL-BP-GL
(3.9%), WC-TG-HDL-BP and the combination including
all five traits (both 3.5%).
In men the estimated 10-year risk for MI for the com-
bination TG-HDL-GL was 9-fold higher compared to
women (15.0 vs. 1.7%), and for the combination HDL-
B P - G La l m o s t5 - f o l dh i g h e rc o m p a r e dt ow o m e n( m e n
8.1%, women 1.8%)
Combination types and 10-year risk for cardiovascular
death (ESC Score)
Since the ESC score predicts fatal cardiovascular events,
the ESC risk estimates are much lower compared to the
PROCAM risk estimates, latter which predicts fatal and
non-fatal events.
Men aged between 35 and 65 years without MetS had
an estimated mean 10-year risk of 2.2% (95%-CI: 2.1%-
2.3%) for fatal MI, whereas the mean 10-year risk of
men with MetS resulted in a mean age-standardized risk
of 3.0% (95%-CI: 3.0%-3.1%) (Figure 4). Strikingly, we
observed three combinations that resulted in lower risk
scores (1.7%-2.0%), compared to the mean risk score of
all men without MetS. One of these combinations
included even four traits (WC-TG-HDL-GL). All combi-
nations with lower risk estimates include - as in
Figure 1 Prevalence (crude) of all 16 combinations in subjects with MetS. In the lower columns: 5 combinations more prevalent in the
young, upper columns: 11 combinations more prevalent in the elderly.
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cose and are more frequent in the older men. However,
of those five combinations with the highest scores
(>3.8%), four were combinations with 4-5 risk factors,
including one risk factor combination which is more
prevalent in the younger (WC-TG-HDL-BP, cf. table 2).
We observed a very similar pattern in women, whose
E S Cs c o r e sw e r ec o m p u t e df o rt h ea g er a n g e4 6 - 6 5
years (Figure 5). Women without MetS had an ESC risk
score of 1.2%, whereas those with MetS had an age-
standardized risk score of 1.8%. As in men we identified
three combinations with lower risk estimates, which are
the same as in men, although on an apparently lower
risk level. As in men the combinations TG-HDL-BP-GL
and WC-TG-HDL-BP resulted in the highest estimated
ESC scores (3.0 and 2.1%, resp.), the latter again a com-
bination which was to be found most often within the
younger age groups (cf. table 2).
Discussion
A sufficient sample size of this German-wide cross-sec-
tional study made it possible to calculate all 16 possible
combinations of MetS and to analyze these in detail
according to sex and an age-group, ranging from 18-99
years. The results of our study show a large variation of
the 16 possible combinations with WC-BP-GL as the
most frequent combination. An uneven distribution was
observed regarding age and sex. Any combination with-
out GL was more frequent in young subjects while any
combination with GL was more frequent in the elderly.
Table 2 Prevalence of all 16 combination types according to age-groups and sex
Combinations of MetS 18-30 years
% (95%-CI)
1
31-45 years
% (95%-CI)
46-60 years
% (95%-CI)
61-75 years
% (95%-CI)
76-99 years
% (95%-CI)
WC TG HDL BP GL
Combinations more
frequent in the young
Men Women Men Women Men Women Men Women Men Women
WC TG HDL BP - 10.9
(4.5-21.3)
13.3
(6.8-22.5)
9.0
(6.1-12.7)
10.5
(7.6-14.0)
3.3
(2.2-4.6)
7.4
(5.9-9.2)
1.9
(1.1-2.9)
4.1
(3.1-5.4)
1.8
(0.5-4.4)
3.5
(2.0-5.6)
WC TG HDL - - 0 9.6
(4.3-18.1)
3.7
(1.9-6.4)
7.6
(5.2-10.8)
1.5
(0.8-2.5)
2.7
(1.8-3.9)
0.3
(0.1-0.9)
1.0
(0.5-1.7)
0 0.7
(0.1-1.9)
WC TG - BP - 37.5
(25.7-50.5)
13.3
(6.8-22.5)
22.4
(17.9-27.3)
12.6
(9.4-16.4)
16.5
(14.2-19.0)
14.7
(12.6-17.0)
10.0
(8.2-12.0)
13.0
(11.2-15.0)
7.5
(4.4-11.7)
11.1
(8.4-14.4)
WC - HDL BP - 12.5
(5.6-23.2)
39.8
(29.2-51.1)
6.5
(4.1-9.8)
27.6
(23.1-32.3)
2.0
(1.2-3.1)
9.7
(8.0-11.7)
2.5
(1.6-3.7)
4.3
(3.3-5.6)
3.5
(1.5-6.8)
3.7
(2.2-5.9)
- TG HDL BP - 18.8
(10.1-30.5)
2.4
(0.3-8.4)
10.3
(7.2-14.1)
5.2
(3.2-8.0)
2.9
(1.9-4.1)
1.9
(1.1-2.9)
1.3
(0.7-2.2)
1.9
(1.2-2.8)
2.2
(0.7-5.0)
1.1
(0.4-2.5)
Combinations more frequent in the elderly
WC - - BP GL 1.6
(0.0-8.4)
4.8
(1.3-11.9)
14.6
(10.9-18.9)
10.8
(7.8-14.3)
25.9
(23.1-28.8)
27.0
(24.3-29.8)
33.8
(30.9-36.9)
33.7
(31.1-36.5)
35.5
(29.3-42.1)
32.7
(28.4-37.2)
- TG - BP GL 0
-
0
-
8.7
(5.9-12.3)
0.8
(0.2-2.3)
10.3
(8.5-12.5)
2.6
(1.7-3.8)
10.2
(8.4-12.3)
2.7
(1.9-3.8)
10.1
(6.5-14.8)
7.2
(5.0-10.0)
WC TG - - GL 0
-
1.2
(0.0-6.5)
1.6
(0.5-3.6)
1.6
(0.6-3.4)
4.4
(3.2-6.0)
2.0
(1.3-3.1)
3.1
(2.1-4.4)
3.1
(2.2-4.2)
2.6
(1.0-5.6)
2.2
(1.1-4.0)
WC TG HDL BP GL 3.1
(0.4-10.8)
6.0
(2.0-13.5)
3.7
(1.9-6.4)
5.2
(3.2-8.0)
7.1
(5.5-8.9)
8.4
(6.8-10.2)
6.3
(4.9-8.0)
8.7
(7.2-10.5)
4.8
(2.4-8.5)
9.6
(7.1-12.7)
WC TG HDL - GL 0
-
0
-
2.2
(0.9-4.4)
3.4
(1.8-5.8)
1.3
(0.7-2.2)
2.6
(1.7-3.8)
2.1
(1.3-3.2)
1.8
(1.1-2.7)
1.3
(0.3-3.8)
1.3
(0.5-2.8)
WC TG - BP GL 4.7
(1.0-13.1)
1.2
(0.0-6.5)
9.6
(6.6-13.4)
3.9
(2.2-6.4)
16.4
(14.1-18.9)
12.3
(10.3-14.4)
20.0
(17.6-22.6)
15.7
(13.7-17.9)
18.9
(14.0-24.6)
12.9
(9.9-16.3)
WC - HDL BP GL 1.6
(0.0-8.4)
6.0
(2.0-13.5)
1.2
(0.3-3.2)
6.3
(4.1-9.2)
2.3
(1.5-3.5)
5.3
(4.0-6.8)
3.8
(2.7-5.2)
6.0
(4.8-7.5)
2.6
(1.0-5.6)
6.3
(4.3-9.0)
- TG HDL BP GL 1.6
(0.0-8.4)
0
-
3.4
(1.7-6.0)
0.5
(0.1-1.9)
2.6
(1.7-3.9)
0.7
(0.3-1.4)
2.4
(1.5-3.5)
1.6
(1.0-2.5)
3.1
(1.2-6.2)
3.3
(1.8-5.3)
- - HDL BP GL 3.1
(0.4-10.8)
1.2
(0.0-6.5)
0.6
(0.1-2.2)
1.0
(0.3-2.7)
1.4
(0.7-2.3)
0.7
(0.3-1.4)
0.9
(0.4-1.7)
0.8
(0.4-1.5)
4.4
(2.1-7.9)
3.5
(2.0-5.6)
WC - HDL - GL 1.6
(0.0-8.4)
1.2
(0.0-6.5)
1.6
(0.5-3.6)
1.8
(0.7-3.8)
1.1
(0.5-1.9)
1.4
(0.8-2.3)
0.9
(0.4-1.7)
1.2
(0.7-2.0)
0.4
(0.0-2.4)
0.7
(0.1-1.9)
- TG HDL - GL 3.1
(0.4-10.8)
0
-
0.9
(0.2-2.7)
1.0
(0.3-2.7)
1.2
(0.6-2.1)
0.7
(0.3-1.4)
0.6
(0.2-1.3)
0.2
(0.1-0.7)
1.3
(0.3-3.8)
0.4
(0.1-1.6)
WC, waist circumference; TG- triglycerides; HDL, High Density Lipoproteins; elevated BP, blood pressure; GL, elevated blood glucose. For cut points used see
methods; 95%-CI, 95% confidence intervals; the higher prevalence in comparing men and women is in bold;
1 Percent of MetS prevalence in specific group defined by age and gender
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Page 6 of 12Figure 2 Age-standardized 10-year risk of myocardial infarction (PROCAM) for men with and men without MetS (reference) and all 16
combinations. In the lower columns: 5 combinations more prevalent in the young; upper columns: 11 combinations more prevalent in the
elderly.
Figure 3 Age-standardized 10-year risk of myocardial infarction (PROCAM) for women with and without MetS (reference) and all 16
combinations. In the lower columns: 5 combinations more prevalent in the young; upper columns: 11 combinations more prevalent in the
elderly.
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Page 7 of 12Figure 4 Age-standardized estimated 10-year risk of fatal cardiovascular disease (ESC) for men with and without MetS (reference) and
for all 16 combinations. In the lower columns: 5 combinations more prevalent in the young; upper columns: 11 combinations more prevalent
in the elderly.
Figure 5 Age-standardized estimated 10-year risk of fatal cardiovascular disease (ESC) for women with and without MetS (reference)
and for all 16 combinations. In the lower columns: 5 combinations more prevalent in the young; upper columns: 11 combinations more
prevalent in the elderly.
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Page 8 of 12On the other hand any combination with dyslipidemia
(TG, HDL) was more frequent in younger subjects,
whereas these combinations were less prevalent in older
subjects. The highest impact on an estimated 10-year
risk for MI (PROCAM) was observed with TG-HDL-
GL-BP in both sexes and TG-HDL-GL in men and TG-
HDL-BP in women. However, we could identify combi-
nations with lower or at least equal risks of non-fatal
and fatal MI compared to participants without MetS.
Prevalence of different combination types
The literature concerning combination types in subjects
with the MetS is scarce and we identified only few arti-
cles dealing with a related topic [11,12,18,28-30]. Thano-
poulou and co-workers examined 1,833 randomly
selected non-diabetic subjects between 22 and 74 years
in five different countries (Algeria, Bulgaria, Egypt, Italy
and Greece), measured the prevalence of possible risk
factor combinations and compared this to expected fre-
quencies from mathematical modelling [29]. The preva-
lence of MetS between the countries ranged form 6% to
37%. The most frequent combination type was WC-
HDL-BP (31% of all subjects with MetS) followed by
TG-HDL-BP (23%) and WC-TG-HDL-BP (19%).
Respective frequencies in our sample were 7%, 3%, and
5%. The combination with the highest prevalence in our
sample WC-BP-GL with 28% was 0.6% in the Thano-
poulou sample. Reasons for these gross differences in
prevalence rates might be in part explained by a couple
of reasons: (1) our rates for this comparison were not
age- and sex-adjusted (GEMCAS: 39% men, age-range
18-99 years) and the data of the Thanopoulou sample
were not stratified by sex (50% men), (2) Thanopoulou
et al. used a different definition of the MetS, and (3)
their sample is considerably younger (ranging from 39
years in Egypt to 50 years in Italy-Pavia) than our GEM-
CAS sample (52 years). Notably, those combinations
that are most frequent in the Thanopoulou sample are
those that are most frequent in the younger age-groups
in our sample and vice versa. (4) Finally, regarding the
unequal distribution of combinations between the sexes
and age-groups in our sample, the informative value of
the prevalence in Thanopoulou et al. condensed from 6
different study centres with varying sex ratio, age-range
and ethnicity, might not be an appropriate comparison
in this context here.
Rodriguez-Colon et al. analyzed data from the popula-
tion based Atherosclerosis Risk in Communities (ARIC)
study. About 15,000 stroke-free individuals with 39%
having the MetS were followed over 9 years [12]. The
prevalence of individual combinations was not reported
but the age, gender and race adjusted rates of 7 recom-
bined combination clusters. Combination cluster defined
b yt h ep r e s e n c eo fe i t h e rB Po rG Lo rb o t hB Pa n dG L
were most prevalent (24%, 23% respectively). Combina-
tions with 4 traits including BP and GL were present in
19% of MetS subjects. The high prevalence of both BP
and GL is well compatible with our own data where BP
and GL were most frequent at least in the elderly.
Hanefeld and colleagues studied in a representative
sample of German patients with type 2 DM the preva-
lence of the MetS by AHA/NHBLI criteria, its single
traits and their combinations [19]. Although a direct
comparison to our results is not feasible, it is striking
that this group also found a large heterogeneity in the
prevalence of the different MetS combinations, with dis-
tinct sex differences.
One major difficulty of the comparison of our results
with results from these studies is the definition of MetS
used. Criteria for defining WC, TG and HDL were iden-
tical; the threshold of BP was lower in the studies of
Thanopoulou and Rodriguez-Colon (≥135/≥85 vs. ≥130/
≥85 mmHg) while the threshold for fasting glucose was
≥110 mg/dl in the Thanopoulou study [29] but ≥100
mg/dl in the Rodriguez-Colon study [12] and ours.
Further, Thanopoulou considered antihypertensive drug
treatment, Rodriguez-Colon antihypertensive and anti-
diabetic drug treatment whileo n l ya n t i d i a b e t i cd r u g
treatment was considered by us. Finally, individuals with
known diabetes were included into Rodriguez-Colon
and our study but not in the one by Thanopoulou. In a
former analysis we could show that different definitions
result in a considerable different prevalence, i.e. the
exclusion of pharmacotherapy according to AHA/
NHLBI 2004 definition distinctly lowered the prevalence
of MetS [20]. Another explanation might be born in the
different population investigated, i.e. primary care vs.
population based [12,29]. This however would suggest
an even higher prevalence of MetS in our study which
was not the case (20% in our study, 27% and 39% in
those studies). Finally, in our study we performed a
complete case analyses and made sure that subjects fall-
ing under one combination of the higher order - e.g.
four risk factors present - are not simultaneously falling
under the combinations with lower order and less cri-
teria - e.g. any three of the above mentioned four. We
expect striking differences in the prevalence rate, if this
methodological approach is not applied. However, only
one publication [29] reported on this methodological
aspect.
Influence of age and gender
Our study demonstrated a substantial influence of age
and gender on the prevalence of combinations. Every
combination that included GL was more prevalent in
the elderly than in young individuals. A particular steep
incline in prevalence was observed for combinations
that did not include lowered HDL. In an earlier
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Page 9 of 12publication of our data we reported that GL was steeply
increasing with age while HDL and for men TG showed
a strong decline [31]. Thanopoulou [29] and Rodriguez-
C o l o n[ 1 2 ]r e p o r t e dn od a t ao nt h ei n f l u e n c eo fa g eo r
gender on combination prevalence rates beyond docu-
menting a rise of MetS cases with age. Rodriguez-Colon
reported however higher rates of elevated WC in
women and higher rates of HDL, TG and GL in men.
This is identical to our findings, except that low HDL
was more frequent in women in our cohort [31].
In our study a particularly steep incline was observed
in both men and women with age for WC-BP-GL with
slightly lesser inclines for TG-BP-GL and WC-TG-GL
(men > women). This is reasonable given that GL gains
and HDL looses importance in the elderly [31]. There-
fore any combination with GL but not HDL should be
highly prevalent in these subjects. On the other hand
and this is supported by the data, any combination with
low HDL but not GL should be more prevalent in
young subjects. This shift in risk factor prevalence could
be caused time dependent (years) in that low physical
activity may translate into low HDL values first and
then lead to insulin resistance in a second step. These
assumptions are supported by recent findings from [32].
MetS combinations and cardiovascular risk
MetS is indicative of an increased risk for cardiovascular
disease morbidity and mortality [33]. In Framingham,
the MetS alone predicted about 25% of all new-onset
cardiovascular disease. In the absence of diabetes, the
MetS generally did not rise 10-year risk for CHD to
>20%. Ten-year risk in men with MetS generally ranged
from 10%-20%. Framingham women with MetS had
relatively few CHD events during the course of the 8-
year follow-up. The 10-year risk for CHD in most
women in this relatively young cohort did not exceed
10%. These data essentially were confirmed in the pre-
sent dataset with peak risks for MI estimated with the
PROCAM algorithm of 15% for men and 4% for women.
In our study all combinations in the younger men
were accompanied by a considerably higher risk estimate
f o rM I( P R O C A M )c o m p a r e dt om e nw i t h o u tM e t S .
Regardless, we found extremely heterogeneously distrib-
uted risks for MI. Even more, for fatal MI (ESC) we
identified combinations that resulted in distinct lower
(although not significant) or equal ESC risk scores and
one of these combinations consisted of four traits of
MetS (WC-TG-HDL-GL). Our data suggests that the
previous assumption - that each combination of the
MetS uniformly increases the risk for cardiovascular
outcomes - might not hold true and supports the find-
ings of a French [28] and the Framingham offspring
study [30]. Therefore, it is not surprising that contro-
versy exists over whether a diagnosis of MetS provides
more useful information about CVD risk than its indivi-
dual components do. An alternative has been proposed
by Franks and Olsson [9], suggesting to include only the
features that are uniquely informative and to weight
each of these components by an empirical value. Of
course this supposition must be examined in prospective
studies, since our cross-sectional approach might have
introduced bias in terms of the temporal occurrence of
a parameter value (i.e. waist circumference) and CVD.
There was however a strong variation of the estimated
risk in relation of the combination detected in a particu-
lar individual. Low HDL was a frequent component of
combinations in high risk subjects of either gender for
MI (PROCAM) and cardiovascular death (ESC score).
GL was highly prevalent in men but not so in women.
Elevated blood pressure was a component in many high
risk combination types. Rodriguez-Colon et al. [12] ana-
lyzed the impact of combinations on the incidence of
stroke in about 15,000 subjects and found 1) a linear
relationship between the number of risk factors and the
r i s ko fi n c i d e n ts t r o k ea n d2 )t h a tp e r s o n sw i t hc o m b i -
nation types including either elevated BP or GL had the
highest risk for incident stroke (hazard ratio 2.7-4.2)
than MetS without these 2 components (hazard ratio
≤2.0). Although we also included individuals with stroke
(3.7% of men and 2.0% women with stroke/TIA in the
past [34]) and investigated a primary care sample our
results fit with these observations and enhance these by
data on the incidence of myocardial infarction and car-
diovascular disease related death.
Strength and Limitation
The strengths of the study are the sample size, the
nationwide approach and the assessment of the MetS as
primary study target, so comprising all required vari-
ables as original measures. However, the participants are
strictly speaking not a real population-based sample, but
close to being so. Some participants meeting MetS cri-
teria might avoid attending their physician because they
are in denial, in this case an underestimation of the pre-
valence would have been occurred. On the other hand,
the estimated prevalence might be too high because the
healthy population does not routinely visit their physi-
cian. However, 91.8% of the adult persons in Germany
consult a general practitioner during one year [35].
Furthermore, characteristics of our sample are compar-
able to other German population-based samples and to
German federal statistical data i.e. with regard to
anthropometric measures, smoking status, marital status,
schooling, and unemployment rate, the latter which was
in Germany in October 2005 10.4%, in our study based
on self-reports 10.2% after adjusting for structural differ-
ences. However, the proportion of participants with
chronic diseases (diabetes, CVD) is higher than
Moebus et al. Cardiovascular Diabetology 2010, 9:34
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Page 10 of 12compared to population-based sample, but still lower
than real patient-based samples [36].
A further possible limitation of our approach to base
risk estimates on PROCAM [26] and ESC scores [27]
deserves notion. The definition of the MetS is of parti-
cular diagnostic value if it indicates an incremental risk
over adding the unique traits of the MetS into a usual
risk scoring model. This cannot be shown by our cross-
sectional design. For the article on the definition of the
MetS by Grundy et al. [4] it was tested whether the
MetS carries an incremental risk beyond the usual risk
factors of the Framingham algorithm. They found that
most of the MetS associated risk was well captured by
age, blood pressure, total cholesterol, diabetes and HDL
without any significant further contribution of other risk
factors.
Conclusions
The data of GEMCAS provide an ample sample to
explore the combination types of the MetS. Although
about on third of the study population was diagnosed as
having the MetS based mainly on increased WC, ele-
vated BP, and impaired fasting GL, there was still a
large variation in the prevalence of the possible 16 com-
bination types and their association to cardiovascular
risk. The importance of different combinations of MetS
changes with age and between genders putting emphasis
on a tailored approach towards very young or very old
subjects. This knowledge may guide clinicians to effec-
tively screen individuals and prioritize diagnostic proce-
dures depending on age and gender.
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